Bormann joins The Jackson Laboratory as Vice President, Translational Science and Network Alliances

BJ Bormann Joins The Jackson Laboratory as Vice President, Translational Science and Network Alliances

BJ Bormann has joined nonprofit biomedical research institution, The Jackson Laboratory (JAX), as vice president, translational science and network alliances.

According to Executive Vice President and COO Chuck Hewett, in this newly created role, Bormann will identify and advance new business opportunities arising out of the Laboratory’s research and development strategies and innovations.

“We look forward to working together to build new business and strategic collaborations. BJ will direct technology licensing and other intellectual property related business, and facilitate the creation of spin-offs,” Hewett said. “With one foot in science and the other in business, BJ has the ideal experience and knowledge for this new role at JAX, and we’re thrilled she’s joined our team.” 

Bormann, who joins JAX with nearly 30 years of experience in pharmaceutical and academic science, and leadership in biotech and pharmaceutical business development and licensing, served as senior vice president responsible for worldwide alliances, licensing and business development at Boehringer Ingelheim Pharmaceuticals, Inc., along with a number of positions at Pfizer, Inc. (NYSE: PFE), including vice president of Pfizer Global Research and Development and the global head of Strategic Alliances. Bormann most recently served in the biotechnology area as CEO of Supportive Therapeutics, LLC, as CEO of Pivot Pharmaceuticals (OTC: PVOTF) and CEO of Harbour Antibodies based in the Netherlands.

She currently serves on the board of directors of various companies, including Supportive Therapeutics, LLC, the nonprofit Institute for Pediatric Innovation, and Bioline RX (BLRX: NASDAQ). 

“There are so many creative and out-of-the-box projects going on at JAX – it’s very exciting to see what our scientific faculty is accomplishing and what a difference they can make to human health,” Bormann said. “I’m so pleased to have the opportunity to share JAX’s cutting-edge, world-class science with new strategic collaborators, help accelerate the development of new treatments and diagnostics, and advance JAX’s mission.”

Bormann received her Ph.D. in biomedical science from the University of Connecticut Health Center and her B.Sc. from Fairfield University in biology.  She completed her postdoctoral training at Yale Medical School in the department of pathology.